SEEL Snapshot
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing of novel technologies and therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorder and post-traumatic stress disorder; SLS-005, a protein stabilizer for the treatment of Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with PD; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; SLS-004 for the treatment of PD; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. Seelos Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York.
Market Capitalization$217,640,528
Price to Sales421.90
Earnings per Share$-0.8120
PE Ratio0.7803
Most Recent Close$3.0200
52 Week High$4.44
52 Week Low$0.4195
50-Day Moving Average$2.7574
200-Day Moving Average$1.4182
All data are from Alpha Vantage as of today. For more infomation on SEEL see Stock Dividend, Valuation, Price and Financial Data for Investors